Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 10,876
Sort by:

Investigation Report on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2021-2025

US$ 2,600.00

Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) is an effective drug for the prevention and treatment of neutropenia or deficiency caused by tumor radiotherapy or chemo...

May 2021 50 pages

Investigation Report on China's Piperacillin and Tazobactam Market 2021-2025

US$ 2,600.00

Piperacillin and Tazobactam is a compound anti-infective drug composed of piperacillin (semi-synthetic penicillin antibiotic) and tazobactam (?-lactamase inhibitor). It is suitable for moderate and se...

May 2021 50 pages

Investigation Report on China's Propofol Market 2021-2025

US$ 2,600.00

Propofol is a short-acting intravenous anesthetic. Its uses include the induction and maintenance of general anesthesia, sedation for mechanically ventilated adults, and procedural sedation. It is als...

May 2021 50 pages

Investigation Report on China's Tiotropium Bromide Market 2021-2025

US$ 2,600.00

Tiotropium Bromide, developed by Boehringer Ingelheim International GmbH, is used to treat chronic obstructive pulmonary disease (COPD). Its product SPIRIVA was approved in China in 2006. In 2017, Tio...

May 2021 50 pages

Investigation Report on China's Tocilizumab Market 2021-2025

US$ 2,600.00

The trade name of Tocilizumab is ACTEMRA, which was developed by Roche Pharma (Schweiz) AG. In 2013, its product was firstly approved in China and its indication is RA. Tocilizumab was approved in Chi...

May 2021 50 pages

Investigation Report on China's Voriconazole Market 2021-2025

US$ 2,600.00

Voriconazole is used to treat progressive, potentially life-threatening fungal infections. Its product was developed by Pfizer. It was approved in China in 2004. By 2020, there are 11 manufacturers of...

May 2021 50 pages

Investigation Report on Chinese Compound Amino Acid Market 2021-2025

US$ 2,600.00

Compound Amino Acid is clinically used for patients with insufficient protein intake, malabsorption, and other amino acids that cannot meet the requirements of body metabolism. It was developed by Jap...

May 2021 50 pages

Global Antipsychotic Drugs Market Size study, Antipsychotic Drugs Market by Drug Class (First Generation, Second Generation, Third Generation and Others), by Application (Schizophrenia, Dementia, Bipolar and Unipolar Depression) and Regional Forecasts 2021-2027

US$ 3,750.00

Global Antipsychotic Drugs Market is valued approximately USD 12.67 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 1.95% over the forecast period 2021-2027. A “psyc...

May 2021 200 pages

Drug Testing Market Size, Share & Trends Analysis Report By Product Type (Consumables, Instruments, Rapid Testing Devices, Services), By Sample Type, By Drug Type, By End Use, By Region, And Segment Forecasts, 2021 - 2028

US$ 5,950.00

This report can be delivered to the clients within 72 Business Hours Drug Testing Market Growth & Trends The global drug testing market size is expected to reach USD 11.7 billion by 2028, according...

May 2021 120 pages

Investigation Report on China's Dulaglutide Market 2021-2025

US$ 2,600.00

Description Dulaglutide is a weekly long-acting GLP-1 receptor agonist developed by Eli Lilly and was approved to enter China in 2019. Dulaglutide is suitable for the blood glucose control of adult pa...

May 2021 50 pages

Investigation Report on China's Funeral Market 2021-2025

US$ 2,600.00

DESCRIPTION The funeral and interment industry can be divided into four parts from the perspective of service content: funeral services, disposal of remains, cemetery services, and other funeral produ...

May 2021 50 pages

Investigation Report on China's Palbociclib Market 2021-2025

US$ 2,600.00

Description Palbociclib is the world's first selective inhibitor of CDK 4/6 launched by Pfizer. By inhibiting CDK 4/6, Palbociclib restores cell cycle control, thereby blocking tumor cell proliferatio...

May 2021 50 pages

Investigation Report on China's Ustekinumab Market 2021-2025

US$ 2,600.00

Ustekinumab is a monoclonal antibody medication developed by Janssen Pharmaceuticals. It is mainly used to treat psoriasis, Crohn's disease, and ulcerative colitis. Janssen’s Ustekinumab, STELARA was...

May 2021 50 pages

Investigation Report on Chinese Salmeterol/Ticasone Market 2021-2025

US$ 2,600.00

Description Salmeterol/Ticasone is a compound medication used in regular treatment of asthma and chronic obstructive pulmonary disease (COPD). Its original drug was developed by GlaxoSmithKline. In 20...

May 2021 50 pages

Breast Cancer Treatment Drug Markets in China

US$ 4,000.00

China's demand for Breast Cancer Treatment Drug has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high...

May 2021 256 pages

1,3 Beta Glucan Synthase (EC 2.4.1.34) - Drugs in Development, 2021

US$ 3,000.00

1,3 Beta Glucan Synthase (EC 2.4.1.34) - Drugs in Development, 2021 SUMMARY 1,3 Beta Glucan Synthase (EC 2.4.1.34) - Drugs in Development, 2021 provides in depth analysis on 1,3 Beta Glucan Synthase (...

April 2021 30 pages

16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021

US$ 3,000.00

16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 SUMMARY 16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 provides in depth analysis on 16S Ribosomal RNA (16S rRNA) targeted pipeline...

April 2021 85 pages

23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021

US$ 3,000.00

23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 SUMMARY 23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 provides in depth analysis on 23S Ribosomal RNA (23S rRNA) targeted pipeline...

April 2021 70 pages

30S Ribosomal Subunit (30S RNA) - Drugs in Development, 2021

US$ 3,000.00

30S Ribosomal Subunit (30S RNA) - Drugs in Development, 2021 SUMMARY 30S Ribosomal Subunit (30S RNA) - Drugs in Development, 2021 provides in depth analysis on 30S Ribosomal Subunit (30S RNA) targeted...

April 2021 40 pages

3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) - Drugs in Development, 2021

US$ 3,000.00

3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) - Drugs in Development, 2021 SUMMARY 3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) - Drugs in Development, 2021 provides in depth analysis on 3C...

April 2021 60 pages

5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) - Drugs in Development, 2021

US$ 3,000.00

5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1...

April 2021 115 pages

5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or Serotonin 1D Beta Receptor or Serotonin Receptor 1B or HTR1B) - Drugs in Development, 2021

US$ 3,000.00

5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or Serotonin 1D Beta Receptor or Serotonin Receptor 1B or HTR1B) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or S...

April 2021 55 pages

5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D) - Drugs in Development, 2021

US$ 3,000.00

5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D A...

April 2021 60 pages

5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) - Drugs in Development, 2021

US$ 3,000.00

5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) - Drugs in Development, 2021 provides in depth anal...

April 2021 45 pages

5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) - Drugs in Development, 2021

US$ 3,000.00

5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) - Drugs in De...

April 2021 170 pages

5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxytryptamine Receptor 1C or Serotonin Receptor 2C or HTR2C) - Drugs in Development, 2021

US$ 3,000.00

5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxytryptamine Receptor 1C or Serotonin Receptor 2C or HTR2C) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxyt...

April 2021 50 pages

5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) - Drugs in Development, 2021

US$ 3,000.00

5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) - Drugs in Development, 2021 provid...

April 2021 60 pages

5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) - Drugs in Development, 2021

US$ 3,000.00

5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) - Drugs in Developmen...

April 2021 40 pages

5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) - Drugs in Development, 2021

US$ 3,000.00

5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) - Drugs in Deve...

April 2021 40 pages

50S Ribosomal Subunit (50S RNA) - Drugs in Development, 2021

US$ 3,000.00

50S Ribosomal Subunit (50S RNA) - Drugs in Development, 2021 SUMMARY 50S Ribosomal Subunit (50S RNA) - Drugs in Development, 2021 provides in depth analysis on 50S Ribosomal Subunit (50S RNA) targeted...

April 2021 30 pages

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drugs in Development, 2021

US$ 3,000.00

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drugs in Development, 2021 SUMMARY 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drugs in Development, 2021 provides in dept...

April 2021 35 pages

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Drugs in Development, 2021

US$ 3,000.00

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Drugs in Development, 2021 SUMMARY Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14)...

April 2021 30 pages

Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) - Drugs in Development, 2021

US$ 3,000.00

Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) - Drugs in Development, 2021 SUMMARY Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) - Drugs in...

April 2021 30 pages

Achromatopsia (Genetic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Achromatopsia (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Achromatopsia (Genetic Disorders) - Drugs in Development, 2021 provides an overview of the Achromatopsia pipeline landscape. The...

April 2021 30 pages

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A (Genetic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A (Genetic Disorder...

April 2021 35 pages

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B (Genetic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B (Genetic Disorder...

April 2021 35 pages

Acquired (Autoimmune) Hemolytic Anemia (Hematological Disorders) - Drugs in Development, 2021

US$ 2,000.00

Acquired (Autoimmune) Hemolytic Anemia (Hematological Disorders) - Drugs in Development, 2021 SUMMARY Acquired (Autoimmune) Hemolytic Anemia (Hematological Disorders) - Drugs in Development, 2021 prov...

April 2021 50 pages

Acral Lentiginous Melanoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Acral Lentiginous Melanoma (Oncology) - Drugs in Development, 2021 SUMMARY Acral Lentiginous Melanoma (Oncology) - Drugs in Development, 2021 provides an overview of the Acral Lentiginous Melanoma pip...

April 2021 30 pages

Acute Bronchitis (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Acute Bronchitis (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Bronchitis (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Bronchitis pipeline landscape. The rep...

April 2021 30 pages

Acute Coronary Syndrome (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Acute Coronary Syndrome (Cardiovascular) - Drugs in Development, 2021 SUMMARY Acute Coronary Syndrome (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Acute Coronary Syndrome...

April 2021 50 pages

Acute Heart Failure (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Acute Heart Failure (Cardiovascular) - Drugs in Development, 2021 SUMMARY Acute Heart Failure (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Acute Heart Failure pipeline lan...

April 2021 50 pages

Acute Inflammation (Immunology) - Drugs in Development, 2021

US$ 2,000.00

Acute Inflammation (Immunology) - Drugs in Development, 2021 SUMMARY Acute Inflammation (Immunology) - Drugs in Development, 2021 provides an overview of the Acute Inflammation pipeline landscape. The...

April 2021 45 pages

Acute Ischemic Stroke (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Acute Ischemic Stroke (Central Nervous System) - Drugs in Development, 2021 SUMMARY Acute Ischemic Stroke (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Acute Ischem...

April 2021 125 pages

Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Acute Liver Failure pipeline...

April 2021 45 pages

Acute Lung Injury (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Acute Lung Injury (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Lung Injury (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Lung Injury pipeline landscape. The...

April 2021 115 pages

Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 SUMMARY Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Acute Lymphoblastic Lympho...

April 2021 45 pages

Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021

US$ 2,000.00

Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021 SUMMARY Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021 provides an overview of the Acute Opioid Overdosage pipeline...

April 2021 40 pages

Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the Acute Promyelocytic Leukem...

April 2021 35 pages

Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Respiratory Failure...

April 2021 30 pages

Filters

Search

Publishers

1
450
353
174
29
4
837
409
36
27
2,279
77
19
16
2
21
1
16
1
9
9
2,264
5
4
31
6
142
1
17
15
248
651
91
1
373
26
34
724
1
2
16
6
4
84
36
3
4
2
7
15
53
16
26
83
11
32
8
2
17
106
27
19
4
7
3
324
15
1
23
86
24
28
44
296
17
18
2

Regions

131
40
38
37
37
35
32
23
13
10
10
9
9
8
8
8
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
6
6
6
6
6
6
5
5
5
5
4
4
3
3
3
3
3
91
12
354
30
6
6
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
39
6
4
3
3
3
1
1
3
7
9,529

Price

Date

Pages

Offers

9
1